Chemical Nameinotersen
Dosage Form Injection (subcutaneous; 284 mg/1.5 mL)
Drug ClassOligonucleotides
SystemCardiovascular, Musculoskeletal, Skin, Blood, Urinary, Cardiovascular, Nervous
CompanyAkcea Therapeutics
Approval Year2018


  • Indicated for treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults
Last updated on 4/20/2022

More on this drug: Clinical Trials

Document TitleYearSource
Tegsedi (Inotersen) Prescribing Information.2018Akcea Therapeutics, Boston, MA

Have we missed a study, or would you like to comment on a study?